natgillin/translations-raw huggingface dataset:
This set of reactions which includes syndrome of cytokine release, tumour lysis syndrome and anaphylactic and hypersensitivity reactions are described below. 
Ta skupina reakcij, ki vključuje sindrom sproščanja citokinov, sindrom razpada tumorja in anafilaktične ter preobčutljivostne reakcije, je opisana spodaj.
• Detailed information on the risk of PML, the need for timely diagnosis of PML and appropriate measures to diagnose PML 
• podrobne podatke o tveganju za PML, informacije o nujnosti njene pravočasne diagnoze in ustreznih ukrepov za diagnosticiranje te bolezni,
Prednisone dose tapering and the decision to stop prednisone treatment after month 18 were left at the investigator's discretion. 
Zmanjševanje odmerka prednizona in odločitev za prenehanje zdravljenja s prednizonom po 18 mesecih sta bila prepuščena raziskovalčevi presoji.
All IRRs were CTC Grade 1 or 2. 
Vse reakcije, povezane z infuzijo, so bile 1. ali 2. stopnje po CTC.
This is mostly accounted for by IRRs (most frequent during the first treatment course), RA exacerbation and infections all of which were more frequent in the first 6 months of treatment. 
To gre v glavnem pripisati reakcijam, povezanim z infuzijo (ki se najpogosteje pojavljajo v prvem ciklu zdravljenja), poslabšanju revmatoidnega artritisa in okužbam; vse našteto se je pogosteje pojavljalo v prvih 6 mesecih zdravljenja.
The projected median time to progression (TTP) for responding patients was 13.0 months. 
Mediana časa do napredovanja bolezni (TTP, time to progression) je pri odzivnih bolnikih znašala 13,0 meseca.
The transient IgM increase usually returned to at least baseline level within 4 months. 
Prehodna zvišanja IgM so se običajno vrnila vsaj na raven pred zdravljenjem v 4
Azathioprine 59 56 52 50 47 47 44 44 42 41 40 39 36 34 0 Rituximab 58 56 56 56 55 54 54 54 54 54 54 54 52 50 0 
Število preskušancev s hujšim recidivom azatioprin 0 0 3 3 5 5 8 8 9 9 9 10 13 15 17 rituksimab 0 0 0 0 1 1 1 1 1 1 1 1 3 3 3 Število preskušancev s tveganjem azatioprin 59 56 52 50 47 47 44 44 42 41 40 39 36 34 0 rituksimab 58 56 56 56 55 54 54 54 54 54 54 54 52 50 0
The safety information collected during post-marketing experience reflects the expected adverse reaction profile as seen in clinical trials for rituximab (see section 4.4). 
Podatki o varnosti, zbrani v obdobju po prihodu zdravila na trg, odražajo pričakovani profil neželenih učinkov, kot so ga opazili v kliničnih preskušanjih z rituksimabom (glejte poglavje 4.4).
Animal studies did not reveal deleterious effects of rituximab on reproductive organs. 
Študije na živalih niso pokazale škodljivih učinkov rituksimaba na reproduktivne organe.
Since initial improvement of clinical symptoms may be followed by deterioration, these patients should be closely monitored until tumour lysis syndrome and pulmonary infiltration have been resolved or ruled out. 
Ker lahko uvodnemu izboljšanju kliničnih simptomov sledi poslabšanje, je treba takšne bolnike skrbno spremljati, dokler sindrom razpada tumorja in pljučna infiltracija ne mineta oziroma dokler nista izključena.
• you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems. 
• če ste kdaj imeli težave s srcem (npr. angino pektoris, razbijanje srca ali srčno popuščanje) ali težave z dihanjem.
Three of the patients had received two courses of rituximab before enrolment and thus were given a third course in the study. 
Trije od teh bolnikov so bili dvakrat zdravljeni z rituksimabom pred vključitvijo, tako so v študiji prejeli tretje zdravljenje z rituksimabom.
Clinically and statistically significant improvement was also noted on all individual components of the ACR response (tender and swollen joint counts, patient and physician global assessment, disability index scores (HAQ), pain assessment and C-Reactive Proteins (mg/dL). 
Klinično in statistično značilno izboljšanje je bilo opaženo tudi v vseh posameznih komponentah odziva ACR (število bolečih in oteklih sklepov, bolnikova in zdravnikova splošna ocena, ocena glede na indeks nezmožnosti (HAQ), ocena bolečine in C-reaktivnega proteina (CRP) (mg/dl).
Placebo+MTX 
Placebo + metotreksat
What Ritemvia is and what it is used for What you need to know before you use Ritemvia How to use Ritemvia 
Kaj je zdravilo Ritemvia in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Ritemvia Kako uporabljati zdravilo Ritemvia
This finding was not supported by a stepwise logistic regression analysis in which the following factors were identified as prognostic factors: histological type, bcl-2 positivity at baseline, resistance to last chemotherapy and bulky disease. 
Te ugotovitve niso podprli s stopenjsko logistično regresijsko analizo, s katero so ugotovili naslednje prognostične dejavnike: histološki tip, izraženost bcl-2 na začetku zdravljenja, neodzivnost na zadnjo kemoterapijo in obsežna bolezen.
This is because Ritemvia can across the placenta and may affect your baby. 
Zdravilo Ritemvia namreč prehaja skozi posteljico (placento) in lahko škoduje otroku.
Peripheral B cell counts declined below normal following completion of the first dose of rituximab. 
Število perifernih celic B se je po dokončanju prvega odmerka rituksimaba zmanjšalo pod normalno vrednost.
If PML is suspected, further dosing must be suspended until PML has been excluded. 
Ob sumu na PML je treba zdravljenje prekiniti, dokler PML ni izključena.
Table 14 Physical function and quality of life outcomes at week 24 in Trial 1 
Funkcijska zmogljivost in vpliv na kakovost življenja po 24 tednih v preskušanju
Prednisone treatment was tapered and then kept at a low dose (approximately 5 mg per day) for at least 18 months after randomisation. 
Zdravljenje s prednizonom so postopoma zmanjšali in ga nato vzdrževali v majhnem odmerku (približno 5 mg na dan) vsaj 18 mesecev po randomizaciji.
Severe (grade 3/4) neutropenia was reported in 4.2%, anaemia in 1.1% and thrombocytopenia in 1.7% of the patients. 
Huda nevtropenija (3. ali 4. stopnje) se je pojavila pri 4,2% bolnikov, anemija pri 1,1% in trombocitopenija pri 1,7% bolnikov.
Study Treatment, N 
Zdravljenje (n)
• you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine (listed in section 6) 
• ste alergični na rituksimab, druge podobne beljakovine ali katero koli sestavino tega zdravila
How Ritemvia is given How it is given 
Kako se daje zdravilo Ritemvia Kako se zdravilo daje
Your doctor may need to take special care of you during your treatment with Ritemvia. 
Zdravnik bo morda moral biti med zdravljenjem z zdravilom Ritemvia posebej poskrbeti za vas.
However, the higher incidence of neutropenia in patients treated with rituximab and chemotherapy was not associated with a higher incidence of infections and infestations compared to patients treated with chemotherapy alone. 
Toda višje incidence nevtropenije pri bolnikih, ki so prejemali rituksimab v kombinaciji s kemoterapijo, ni spremljala višja incidenca infekcijskih in parazitskih bolezni kot pri bolnikih, zdravljenih samo s kemoterapijo.
Your doctor may prescribe Ritemvia for the treatment of: 
Zdravnik vam lahko zdravilo Ritemvia predpiše za zdravljenje:
The ADRs identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known”. 
Neželeni učinki, ki so jih opazili samo po prihodu zdravila na trg in za katere pogostnosti ni mogoče oceniti, so navedeni v ni znano.
Binet stage A Binet stage B Binet stage C CI: Confidence Interval 
Stopnja po Binetu A Stopnja po Binetu B Stopnja po Binetu C
Frequencies are defined as very common (≥ 1/10), common 
Pogostnost je opredeljena kot zelo pogosta (≥ 1/10), pogosta
Currently, there are limited data on possible drug interactions with rituximab. 
Trenutno je le malo podatkov o mogočih medsebojnih učinkih zdravil pri uporabi zdravila rituksimab.
This is because some people have a fall in their blood pressure while they are being given Ritemvia. 
Nekaterim ljudem se namreč med prejemanjem zdravila Ritemvia krvni tlak zniža;
• general discomfort or feeling uneasy or tired, shaking, signs of flu 
splošno nelagodje, neprijetno počutje ali utrujenost, tresenje, znaki gripe,
The emergence of ADA was not associated with clinical deterioration or with an increased risk of reactions to subsequent infusions in the majority of patients. 
Pojav ADA pri večini bolnikov ni bil povezan s kliničnim poslabšanjem ali povečanim tveganjem za reakcije pri nadaljnjih infuzijah.
Table 16 Percentage of patients who achieved complete remission at 6 months (Intent-to-treat population*) 
Odstotek bolnikov, ki so po 6 mesecih dosegli popolno remisijo (populacija, ki so jo nameravali zdraviti*).
Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146) 
Slika 2: Odzivi ACR za 4 cikle zdravljenja (24 tednov po vsakem ciklu (intraindividualno, znotraj pregledov) pri bolnikih, ki niso zadostno odgovorili zdravljenje z zaviralci TNF (n = 146).
Infections were predominately mild to moderate. 
Okužbe so bile v glavnem blage do zmerne.
Treatment difference (Rituximabcyclophosphamide) 
Razlika zdravljenj (rituksimabciklofosfamid)
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1% after eight doses of rituximab. 
Incidenca simptomov, povezanih z infuzijo, se z nadaljnjimi infuzijami bistveno zmanjšuje in je po osmih odmerkih rituksimaba manjša kot 1%.
Ritemvia can be given alone or with other medicines called “chemotherapy”. 
Zdravilo Ritemvia lahko uporabljamo samostojno ali skupaj z drugimi zdravili, ki jih imenujemo kemoterapija.
The primary outcome measure was the rate of major relapse at month 28. 
Primarno merilo izida je bil delež hujših recidivov po 28 mesecih.
No studies on the effects of rituximab on the ability to drive and use machines have been performed, although the pharmacological activity and adverse reactions reported to date suggest that rituximab would have no or negligible influence on the ability to drive and use machines. 
Študij o vplivu zdravila rituksimab na sposobnost za vožnjo in upravljanje s stroji niso izvedli, čeprav opisano farmakološko delovanje in neželeni učinki kažejo, da vpliva na to ni ali je le zanemarljiv.
150 patients originally randomised to placebo + MTX in Trial 1 received at least one course of RTX + MTX by one year * p <0.05, ** p < 0.001. 
150 bolnikov, ki so v preskušanju 1 sprva prejemali placebo + metotreksat, je do enega leta prejelo vsaj en cikel rituksimaba + metotreksata * p < 0,05; ** p < 0,001.
The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction, and if so, whether these symptoms are possibly suggestive of PML. 
Zdravnik mora oceniti bolnika, da bi ugotovil, ali simptomi kažejo na nevrološko disfunkcijo, in če je tako, ali so lahko povezani s PML.
In all these studies, rituximab pharmacokinetics were dose proportional over the limited dose range studied. 
V vseh preskušanjih je bila farmakokinetika rituksimaba sorazmerna odmerku v omejenem območju odmerkov, ki so ga preučevali.
Table 7 Overview of efficacy results for rituximab maintenance vs. observation at the protocol-defined primary analysis and after 9 years median follow-up (final analysis) 
Pregled učinkovitosti zdravljenja z rituksimabom v primerjavi z opazovanjem v času primarne analize, določene s protokolom, in po mediani spremljanja 9 let (končna analiza)
Gastrointestinal perforation in some cases leading to death has been observed in patients receiving rituximab for treatment of non-Hodgkin's lymphoma. 
Perforacijo prebavil, ki je v nekaterih primerih povzročila smrt, so opazili pri bolnikih, ki so prejemali rituksimab za zdravljenje ne-Hodgkinovega limfoma.
The recommended initial rate for infusion is 50 mg/h; after the first 30 minutes, it can be escalated in 50 mg/h increments every 30 minutes, to a maximum of 400 mg/h. 
Priporočena začetna hitrost infundiranja je 50 mg/h; po prvih 30 minutah jo lahko vsakih 30 minut povečujemo po 50 mg/h, dokler ne dosežemo največje hitrosti infundiranja 400 mg/h.
Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali mišje beljakovine ali na katero koli drugo pomožno snov, navedeno v poglavju 6.1.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta.
The efficacy and safety of rituximab in alleviating the symptoms and signs of rheumatoid arthritis in patients with an inadequate response to TNF-inhibitors was demonstrated in a pivotal randomised, controlled, double-blind, multicentre trial (Trial 1). 
Učinkovitost in varnost rituksimaba v lajšanju simptomov in znakov revmatoidnega artritisa pri bolnikih, ki niso zadostno odgovorili na zdravljenje z zaviralci TNF, sta bili dokazani v ključnem randomiziranem, kontroliranem, dvojno slepem, multicentričnem preskušanju (preskušanje 1).
• infections such as herpes infections and eye infection 
okužbe, kot so okužbe z virusom herpes in očesne okužbe,
Significant improvement in health related quality of life was also demonstrated with significant improvement in both the physical health score (PHS) and mental health score (MHS) of the SF-36. 
Ugotovljeno je bilo tudi značilno izboljšanje zdravstvenih kazalcev kakovosti življenja z značilnim izboljšanjem ocene telesnega zdravja (PHS, Physical Health Score) in duševnega zdravja (MHS, Mental
Duration of response* Disease free survival (DFS)** Time to new treatment 
Trajanje odgovora* Preživetje brez bolezni** Čas do novega zdravljenja
This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) during and after the 4 week induction course of Ritemvia treatment. 
Temu mora slediti 1 mg/kg/dan prednizona peroralno (odmerek ne sme preseči 80 mg/dan in ga je treba zmanjšati, kolikor hitro je mogoče glede na klinične potrebe) med in po 4-tedenskem indukcijskem zdravljenjem z zdravilom Ritemvia in po njem.
A total of 1078 patients responded to induction therapy, of which 1018 were randomised to rituximab maintenance therapy (n=505) or observation (n=513). 
Na indukcijsko zdravljenje se je odzvalo 1.078 bolnikov, od teh jih je bilo 1.018 randomiziranih v vzdrževalno zdravljenje z rituksimabom (n=505) ali v opazovanje (n=513).
There are limited data from clinical trials to fully assess the safety of the sequential use of other DMARDs (including TNF inhibitors and other biologics) following rituximab (see section 4.5). 
Iz kliničnih preskušanj ni zadostnih podatkov za popolno oceno varnosti uporabe drugih DMARD (vključno z zaviralci TNF in drugimi biološkimi zdravili), ki sledijo zdravljenju z zdravilom rituksimab (glejte poglavje 4.5).
Neutropenia can occur several months after the administration of rituximab (see section 4.4). 
Nevtropenija se lahko pojavi več mesecev po dajanju rituksimaba (glejte poglavje 4.4).
At Week 24, patients who were seropositive to RF and/or anti-CCP at baseline had a significantly increased probability of achieving ACR20 and 50 responses compared to seronegative patients (p=0.0312 and p=0.0096) (Table 15). 
Po 24 tednih so imeli bolniki, ki so bili izhodiščno seropozitivni za RF in/ali anti-CCP, značilno večjo verjetnost, da dosežejo odziv ACR20 in 50, v primerjavi s seronegativnimi bolniki (p=0,0312 in p=0,0096) (preglednica 15).
Herpes virus infection Herpes zoster Oral herpes Conjunctivitis 
Infekcijske in parazitske bolezni okužba z virusom herpes herpes zoster oralni herpes konjunktivitis
Therefore vaccination with live virus vaccines is not recommended whilst on rituximab or whilst peripherally B cell depleted. 
Cepljenje z živimi virusnimi cepivi zato ni priporočljivo med zdravljenjem z zdravilom rituksimab ali medtem, ko je število perifernih celic B zmanjšano.
The trial demonstrated non-inferiority of rituximab to cyclophosphamide for complete remission (CR) at 6 months (Table 16). 
Preskušanje je dokazalo neinferiornost rituksimaba v primerjavi s ciklofosfamidom glede popolne remisije po 6 mesecih (preglednica 16).
The healthcare provider should also consider resuming or increasing the patient's glucocorticoid dose based on clinical evaluation. 
Zdravnik mora na podlagi klinične ocene razmisliti tudi o ponovni uvedbi ali povečanju bolnikovega odmerka glukokortikoida.
The proportion of patients with IgG levels below the LLN was about 60% in the rituximab group throughout the 2 year treatment period, while it decreased in the observation group (36% after 2 years). 
Delež bolnikov s koncentracijo IgG pod spodnjo mejo normalne vrednosti je bil med 2-letnim zdravljenjem približno 60% v skupini, ki je prejemala rituksimab, v opazovani skupini pa se je zmanjšal (36% po dveh letih).
A statistically significant correlation was noted between response rates and bone marrow involvement. 
Statistično značilno korelacijo so opazili med deležem odgovorov in infiltracijo kostnega mozga.
Patients must be monitored at regular intervals for any new or worsening neurological symptoms or signs that may be suggestive of PML. 
Pri bolnikih je treba redno spremljati pojave novih ali poslabšanje nevroloških simptomov ali znakov, ki bi lahko nakazovali na PML.
Abbreviation: NS, non significant 
Kratica: NS, ni značilno (Not Significant).
There was no difference between the treatment groups in the incidence of other thromboembolic events. 
Incidenca drugih trombemboličnih dogodkov se med terapevtskima skupinama ni razlikovala.
Event free survival Response rate (CR, nPR, or PR) 
Preživetje brez dogodka Odgovor (CR, nPR ali PR)
The median PFS was 42.2 months in the rituximab maintenance arm compared to 14.3 months in the observation arm. 
Mediana PFS je bila 42,2 meseca v skupini, ki je prejemala vzdrževalno zdravljenje z rituksimabom, in 14,3 meseca v opazovani skupini.
In rheumatoid arthritis most infusion-related events reported in clinical trials were mild to moderate in severity. 
Pri revmatoidnem artritisu je bila večina z infuzijo povezanih dogodkov, o katerih so poročali v kliničnih preskušanjih, po resnosti blagih do zmernih.
Reactions attributed to hypersensitivity have been reported less frequently than those attributed to cytokine release. 
O preobčutljivostnih reakcijah so poročali redkeje kot o reakcijah zaradi sproščanja citokinov.
Rituximab has been used in 21 patients who underwent autologous bone marrow transplantation and other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity. 
Rituksimab so uporabili pri 21 bolnikih po avtologni transplantaciji kostnega mozga in pri drugih rizičnih skupinah, pri katerih je pričakovano zmanjšano delovanje kostnega mozga, ne da bi se pojavila mielotoksičnost.
The overall incidence of IRRs in clinical trials was 23% with the first infusion and decreased with subsequent infusions. 
Celokupna incidenca z infuzijo povezanih reakcij je v kliničnih preskušanjih znašala 23 % pri prvi infuziji in se je pri nadaljnjih infuzijah zmanjšala.
Talk to your doctor, pharmacist or nurse before you are given Ritemvia if: 
Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Ritemvia:
There was no cumulative toxicity in terms of infections reported over a 2-year treatment period. 
Pri okužbah, o katerih so poročali med dveletnim zdravljenjem, kumulativne toksičnosti ni bilo.
Rituximab should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low). 
Zdravila rituksimab se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo, sepso ali oportunističnimi okužbami, glejte poglavje 4.3) ali hudo imunokompromitiranim bolnikom (npr. pri zelo nizkih vrednostih CD4 ali CD8).
Results from three other randomised trials using rituximab in combination with chemotherapy regimen other than CVP (CHOP, MCP, CHVP/Interferon-α) have also demonstrated significant improvements in response rates, time-dependent parameters as well as in overall survival. 
Rezultati treh drugih randomiziranih preskušanj z uporabo rituksimaba v kombinaciji z drugimi shemami kemoterapije (CHOP, MCP, CHVP/interferon alfa), in ne CVP, so prav tako pokazali značilna izboljšanja deležev odgovora, od časa odvisnih parametrov in celokupnega preživetja.
Observation (N = 167) 
Opazovanje (n = 167)
The highest intravenous dose of rituximab tested in humans to date is 5000 mg (2250 mg/m2), tested in a dose escalation study in patients with CLL. 
Največji do zdaj preizkušen intravenski odmerek rituksimaba pri človeku je 5.000 mg (2.250 mg/m2), preizkušen v študiji povečevanja odmerka pri bolnikih s kronično limfocitno levkemijo.
No incompatibilities between rituximab and polyvinyl chloride or polyethylene bags or infusion sets have been observed. 
Med rituksimabom in vrečkami iz polivinilklorida ali polietilena ali infuzijskimi seti niso ugotovili inkompatibilnosti.
Some cases of late neutropenia occurring more than four weeks after the last infusion of rituximab were reported. 
Poročali so o posameznih primerih pozne nevtropenije, ki se je pojavila več kot 4 tedne po zadnji infuziji rituksimaba.
In studies of rituximab in patients with Waldenstrom's macroglobulinaemia, transient increases in serum IgM levels have been observed following treatment initiation, which may be associated with hyperviscosity and related symptoms. 
Pri bolnikih z Waldenstromovo makroglobulinemijo so v študijah z rituksimabom po začetku zdravljenja opazili prehodna zvišanja koncentracij IgM v serumu, kar pa je lahko povezano s hiperviskoznostjo in sorodnimi simptomi.
A total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for ADA in clinical studies following therapy with rituximab. 
Skupno je bilo 392 od 3.095 (12,7%) bolnikov z revmatoidnim artritisom v kliničnih študijah zdravljenja z rituksimabom pozitivnih na ADA.
• you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris. 
• imate hudo srčno popuščanje ali hudo, neurejeno srčno bolezen in imate tudi granulomatozo s poliangiitisom, mikroskopski poliangiitis ali navadni pemfigus.
This is because in a few cases, Ritemvia could cause hepatitis B to become active again, which can be fatal in very rare cases. 
V maloštevilnih primerih namreč lahko bolezen zaradi zdravila Ritemvia ponovno izbruhne; to je lahko v zelo redkih primerih smrtno.
The primary objective for the study was complete remission (complete epithelialisation and absence of new and/or established lesions) at month 24 without the use of prednisone therapy for two months or more (CRoff for ≥ 2 months). 
Primarni cilj študije je bila popolna remisija (CR - complete remission) (popolna epitelizacija in odsotnost novih in/ali razvitih lezij) po 24 mesecih brez uporabe prednizonskega zdravljenja v obdobju dveh mesecev ali več (CRoff za ≥ 2 meseca).
Ritemvia should be used in combination with CHOP chemotherapy. 
Zdravilo Ritemvia je treba uporabljati v kombinaciji s kemoterapijo CHOP.
Neutropenia was not associated with an observed increase in serious infection in rituximab-treated patients. 
Nevtropenija ni bila povezana z opaznim povečanjem resnih okužb med bolniki, ki so prejemali rituksimab.
Remission-induction therapy included IV prednisone, administered as per the investigator's discretion, preceded in some patients by methylprednisolone pulses, and pulse cyclophosphamide until remission was attained after 4 to 6 months. 
Zdravljenje za indukcijo remisije je vključevalo intravenski prednizon, uporabljen po raziskovalčevi presoji, (nekateri bolniki so pred tem prejemali pulze metilprednizolona) in pulzni ciklofosfamid dokler ni bila dosežena remisija po 4 do 6 mesecih.
CHVP-IFN, R-CHVPIFN, 175 
CHVP-IFN: 183 R-CHVP-IFN: 175